Search alternatives:
significant barriers » significant barrier (Expand Search), significant factors (Expand Search), significant burden (Expand Search)
barriers decrease » larger decrease (Expand Search), barrier disease (Expand Search)
marked decrease » marked increase (Expand Search)
significant barriers » significant barrier (Expand Search), significant factors (Expand Search), significant burden (Expand Search)
barriers decrease » larger decrease (Expand Search), barrier disease (Expand Search)
marked decrease » marked increase (Expand Search)
-
1
CKO mice display decreased skin barrier function and perturbed homeostasis.
Published 2025Subjects: -
2
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
-
3
-
4
-
5
-
6
Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.
Published 2024“…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns = not significant.…”
-
7
Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration.
Published 2025“…<p><b>(A)</b> A significant decrease in the proliferative clonal capacity of U87MG colonies was observed with 70ΜM and 100ΜM SHG-44 treatment. …”
-
8
-
9
-
10
Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations.
Published 2025“…<b>(D)</b> Similarly, U251MG cells showed significantly decreased clonogenic potential upon 100ΜM SHG-44 treatment when compared to 100ΜM cis-platin and the untreated control. …”
-
11
-
12
-
13
-
14
-
15
-
16
Altered expression of genes related to Ca<sup>2+</sup> cycling or myocardial contraction.
Published 2025Subjects: -
17
-
18
-
19
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; <sup>$</sup>(P < 0.05) significant vs. …”
-
20